Table 1 Eligibility criteria

Subjects > 18 years of age

Contraindication for use of ARB

Either gender

Urgent need for revascularization procedure

First episode of acute MI

Severe heart failure (NYHA IV or need for inotropic support)

Typical pain lasting ≥ 20 minutes

Persistent (>1 hour) severe hypotension (systolic blood pressure < 90 mmHg)

ST elevation of more than 1 mm in at least 2 separate leads on the ECG

Refractory or potentially lethal arrhythmias

An echocardiographic LV EF < 50%

Hemodynamically significant right ventricular infarction

Optimal recording of echocardiographic imaging of apical chamber views

Congenital heart disease

Patients who provide written informed consent

Primary valvular disease, severer than mild degree

Idiopathic hypertrophic cardiomyopathy

Concomitant inflammatory cardiomyopathy

Significant renal dysfunction (serum creatinine 2.5 mg/dl)

Significant hepatic dysfunction (serum transaminase more than 3 times normal)

Anemia (hemoglobin < 10 mg/mL or 6 mmol/L)

Psychiatric disorders, alcohol or drug abuse

Life expectancy is less than 1 year

Participation in any other pharmacological study within 2 months

Refusal or inability to provide informal consent